Insider trading · Q3 2026 · CIK 1622229

Cogent Biosciences, Inc. (COGT) insider trading.

In Q3 2026, insiders at Cogent Biosciences, Inc. reported 4 non-derivative transactions on 2 Forms 3, 4 and 5: 0 open-market purchases and 2 sales worth $1.7M.

Transactions
4
Purchases (P)
0
Sales (S)
2
Net shares, P minus S
-45,510
Insiders
1
Last filed
2026-08-31

Insiders

InsiderRelationshipTransactionsBuysSales
Morris ArleneDirector402

Transactions

4 non-derivative rows, newest transaction first. Shares and prices as filed.
DateInsiderCodeSharesPriceOwned afterFiling
2026-08-27Morris ArleneM (A)41,927$5.6441,927Form 4
2026-08-27Morris ArleneS (D)3,161$37.540Form 4
2026-08-27Morris ArleneS (D)42,349$37.093,161Form 4
2026-08-27Morris ArleneM (A)3,583$2.5245,510Form 4

Transaction codes in this quarter

Get COGT insider transactions through the API

Request with your API key
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1622229&limit=100" \
  -H "Authorization: Bearer $SEC_API_KEY"

Insider trading API guide · COGT company page · Cogent Biosciences, Inc. on SEC.gov

Questions

Are insiders buying or selling Cogent Biosciences, Inc. (COGT)?

In Q3 2026, insiders at Cogent Biosciences, Inc. reported 4 non-derivative transactions on 2 Forms 3, 4 and 5: 0 open-market purchases and 2 sales worth $1.7M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.

Where do these Cogent Biosciences, Inc. insider trades come from?

From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.

Source: SEC Insider Transactions Data Sets, Q3 2026, retrieved 2026-10-27. Footnotes, derivative holdings and amendments are in the linked filings. Not investment advice.

Plain-text version for agents and LLMs: /insider-trading/cogt.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.